Abstract:Abstract Abstract 36 Background. Nephrotic syndrome (NS) is frequently accompanied by thromboembolic complications such as renal vein thrombosis, deep vein thrombosis and pulmonary embolism. However, the cause of the hypercoagulable state in NS patients is not understood. In contrast to quiescent cells, membrane-derived microparticles have exposed phosphatidylserine which may support procoagulant enzyme complexes in thrombosis. Objectives. The aim of this work was to measure the type and quantity of MPs that expose PS in NS patients, and to evaluate the associated procoagulant activity (PCA). Methods. The subjects with membranous nephropathy (MN) or minimal change nephrotic syndrome (MCNS) were compared to healthy controls. Flow cytometry and confocal microscopy was used to evaluate microparticles. PCA was determined by clotting time and purified coagulation complex assays. Results. We found that the number of lactadherin+ MPs was significantly higher in each NS group MCNS (3230 ± 536)/MN (4642 ± 697) than that in the controls (1748 ± 239), furthermore, MPs in MN patients are significantly higher than ones in MCNS (P < 0.05; Table 1), which mostly derived from RBC and platelet membranes. The percentage of lactadherin+ RBCs was also significantly increased in each NS group, MN (9.7 ± 3.2%)/MCNS (5.1 ± 2.4%) patients compared to the controls (0.5 ± 0.2%). In addition, the mean percentage of lactadherin+ RBCs in MN showed significantly higher than that in MCNS (P < 0.05). In both NS groups, the percentage of lactadherin+ platelets was significantly higher than that in healthy control subjects (4.1 ± 1.1%) (P < 0.05 for both). Furthermore, patients in MN (11.5 ± 3.1%) also had significantly increased lactadherin+ platelets than in MCNS (7.3 ± 2.3%) (P < 0.05). By confocal laser-scanning microscope, nearly no staining by Alexa Fluro 488-lactadherin could be detected on RBCs or platelets membranes in healthy subjects, whereas a light green fluorescence on RBC and platelet with lactadherin accompanying vesiculation were observed in NS patients. PCA of RBCs/platelets from healthy individuals and NS patients was assessed by recalcification time assays, intrinsic, extrinsic FXa and prothrombinase assays. MPs shedding and PS exposure of RBCs/platelets were highly procoagulant in NS patients and blockade of PS with lactadherin inhibited over 90% of PCA. However, an anti-TF antibody had no significant inhibition effect (Figure 1). Conclusions. This is the first study to show that loss of RBCs/platelets membrane phospholipid asymmetry with increased PS exposure and MPs release may contribute to the hypercoagulable state of NS patients. The extent of PS exposure on cells and MPs may be a marker of thromboembolic risk in these patients. Disclosures: No relevant conflicts of interest to declare.

Surface exposure of phosphatidylserine in pathological cells

Phosphatidylserine targeting for diagnosis and treatment of human diseases

Phosphatidylserine, a death knell

Phosphatidylserine transport in cell life and death

Phosphatidylserine Exposure and Procoagulant Activity in Acute Promyelocytic Leukemia

The role of phosphatidylserine on the membrane in immunity and blood coagulation

The Distribution and Function of Phosphatidylserine in Cellular Membranes

Phosphatidylserine-Mediated Cellular Signaling

Molecular regulations of phosphatidylserine eversion in plasma membrane

Sensing Phosphatidylserine in Cellular Membranes

Platelet membrane phospholipid asymmetry: from the characterization of a scramblase activity to the identification of an essential protein mutated in Scott syndrome

Immunologic Detection of Phosphatidylserine Externalization during Thrombin-Induced Platelet Activation

Metabolism and functions of phosphatidylserine

Phosphatidylserine-Exposing Annexin A1-Positive Extracellular Vesicles: Potential Cancer Biomarkers

Distribution, dynamics and functional roles of phosphatidylserine within the cell

Erythrocytes and Platelets May Contribute to Hypercoagulability in Nephrotic Syndrome Through Enhanced Phosphatidylserine Exposure and Microparticles Release

Intravascular cells and circulating microparticles induce procoagulant activity via phosphatidylserine exposure in heart failure

Oxidation of Phosphatidylserine: a Mechanism for Plasma Membrane Phospholipid Scrambling During Apoptosis?

Inner Mitochondrial Membrane Disruption Links Apoptotic and Agonist-Initiated Phosphatidylserine Externalization in Platelets

Gla-domain mediated targeting of externalized phosphatidylserine for intracellular delivery

Non-apoptotic Phosphatidylserine Externalization Induced by Engagement of Glycosylphosphatidylinositol-anchored Proteins